PDCD1 and neoplasm: However, the main subgroup in a study was Vp4 PVTT, the PFS was 4.9 months, the OS was 9.4 months, and the objective response rate of PVTT based on mRECIST was 61.5% who received PD-1 inhibitor lenvatinib plus radiotherapy in previous study [47]; The intrahepatic tumor objective response rate was 68.3%, and the median OS, PFS was 21.7 months and 14.5 months for patients with main trunk portal vein tumor thrombus who received transarterial chemoembolization plus lenvatinib and PD-1 inhibitors [48].